The Center for Neuro-Oncology is a collaboration across multiple disciplines to provide personalized comprehensive care to patients with tumors of the nervous system and a leading destination center in the state of Indiana and beyond. The center provides excellence in clinical care, research and education for central/peripheral nervous systems tumors and cancer neurology. It’s the mission of the center to deliver optimal patient outcomes, perform cutting-edge research, and educate medical professionals, patients, and caregivers. Patient experience is enhanced through innovation in clinical care, education and research in a state-of-the-art environment.
Vision
The center prioritizes the physical, psychological, cognitive, and spiritual care needs of our patients, and deliver the same high-level support to patients and their caregivers anywhere within the IU Health system. Excellence in neuro-oncology is indispensable to cancer care.
Clinical Programs
The IU Health Neuro-Oncology Brain and Spine Metastases Multi-Disciplinary Clinic was designed to allow our patients to meet their Neuro-Oncology, Neurosurgery, and Radiation Oncology providers during a single educational visit. This allows the patient and their caregiver(s) an opportunity to discuss their diagnosis, treatment options, their healthcare goals and values, and any important next steps.
The Neuro-Oncology Program at Riley Children's Health provides nationally ranked care to children with brain and spinal cord tumors.
Aiming to provide a great patient experience by having a complete multidisciplinary team working together to consolidate care and make it easier for patients. Our focus is on improving the structure of patient care, addressing their total needs, and continuously enhancing the patient experience.
Our goals are to achieve durable local control of CNS disease, ensuring it is neither disabling nor life-threatening, while maintaining a low complication rate of 3% or less for serious or treatment-delaying complications. We aim to get patients back on systemic therapy as quickly as possible and develop a structured pathway to ensure seamless continuity of care for brain metastases patients.
Education
The Neurosurgical Oncology/Skull Base Fellowship in the Department of Neurological Surgery offers a well-rounded experience in managing complex brain tumors. This one-year fellowship opportunity offers participation in operative management of aneurysms and arteriovenous malformations and therefore encompasses a broad range of complex cranial procedures.
The two-year, ACGME-accredited Neurotology Fellowship is available every other year through the Department of Otolaryngology—Head and Neck Surgery. The fellow will master surgical approach during the first year and progress to tumor removal and cranial nerve conservation surgery during the second year.
The one-year Rhinology and Endoscopic Skull Base Surgery Fellowship in the Department of Otolaryngology—Head and Neck Surgery focuses on developing skills in assessment, treatment strategies and surgical techniques used in the management of complex rhinologic and neuro-rhinologic conditions. The fellowship will provide an experience that will prepare the trainee to enter into a career in academic rhinology.
Clinical Research
A randomized, open-label, multicentric, two-arm pivotal trial of SonoCloud-9 combined with carboplatin (CBDCA) vs standard of care lomustine (CCNU) or temozolomide (TMZ) in patients undergoing planned resection for first recurrence glioblastoma, Short Title: SONOBIRD (for SonoCloud for Bbb opening in GBM Recurrent Disease), Carthera study number: SC9-GBM-03 1 enrolled, Recruiting
A phase 1B/2 open-label study to investigate the safety, tolerance and efficacy of drug-resistant immunotherapy with activated, gene modified allogeneic or autologous γδ T cells (Deltex) in combination with maintenance Temozolomide(TMZ) in subjects with recurrent or newly diagnosed glioblastoma PLANNED start-up
CLINICAL Features and Outcomes of Children and Adults with Neurofibromatosis Type 1-Associated High Grade Glioma and Adults with Low Grade Glioma PLANNED start-up
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity. ( Spring Works Therapeutics) 2 enrolled, 1 active Closed to enrollment
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation ( Agios Pharmaceuticals, Inc.) 2 enrolled, 2 active Closed to enrollment
Residual Vestibular Schwannomas: Proposed Age-Tumor-Residual (ATR) Staging System to Predict Future Growth